Abstract
Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Personalized medicine holds great promise for improving therapy outcomes by optimally targeting metabolic pathways.
See related article by Karasinska et al., p. 135
©2019 American Association for Cancer Research.
2019
American Association for Cancer Research.
You do not currently have access to this content.